A formulation of pertuzumab and trastuzumab that health care professionals can administer by subcutaneous injection in a patient’s home instead of intravenously in an infusion center has received approval for adults with certain types of breast cancer.
The recently approved treatment also includes recombinant human hyaluronidase, an enzyme that helps the body absorb other drugs. Sold under the brand name Phesgo, the fixed-dose medication is indicated in combination with chemotherapy for patients with early or metastatic ERBB2 (formerly HER2)-positive breast cancer. Both pertuzumab and trastuzumab bind to the ERBB2 receptor, but in different locations, which is thought to block ERBB2 signaling pathways more completely than either drug alone.
Voelker R. Breast Cancer Drug Can Be Given at Home or in the Clinic. JAMA. 2020;324(5):433. doi:10.1001/jama.2020.13100
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: